ASPEN: Results of a Phase 3 Randomized Trial of Zanubrutinib versus Ibrutinib for Patients with Waldenström Macroglobulinemia (ASCO)
ABSTRACT 06/2020
For more information about this resource, please submit a medical information request.
Presented at the 2020 Annual Meeting of the American Socuety of Clinical Oncology (ASCO), May 29 - May 31, 2020
Abstract: 8007
Rating
